{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:01:42Z","timestamp":1790514102417,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T00:00:00Z","timestamp":1578441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Zhejiang Provincial Medicine Health Science and Technology Program","award":["2018ZB057"],"award-info":[{"award-number":["2018ZB057"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10753-019-01158-z","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T21:02:23Z","timestamp":1578517343000},"page":"712-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Isofraxidin Alleviates Myocardial Infarction Through NLRP3 Inflammasome Inhibition"],"prefix":"10.1007","volume":"43","author":[{"given":"Guofan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9202-7985","authenticated-orcid":false,"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,8]]},"reference":[{"issue":"10186","key":"1158_CR1","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","volume":"393","author":"I Raber","year":"2019","unstructured":"Raber, I., C.P. McCarthy, M. Vaduganathan, D.L. Bhatt, D.A. Wood, J.G.F. Cleland, R.S. Blumenthal, and J.W. McEvoy. 2019. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 393 (10186): 2155\u20132167. https:\/\/doi.org\/10.1016\/S0140-6736(19)30541-0.","journal-title":"Lancet"},{"key":"1158_CR2","doi-asserted-by":"publisher","unstructured":"Oder, D., M.S. Topp, and P. Nordbeck. 2019. Coronary B-cell lymphoma infiltration causing myocardial infarction. European Heart Journal. https:\/\/doi.org\/10.1093\/eurheartj\/ehz538.","DOI":"10.1093\/eurheartj\/ehz538"},{"issue":"4","key":"1158_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jacc.2019.05.044","volume":"74","author":"L Koechlin","year":"2019","unstructured":"Koechlin, L., J. Boeddinghaus, T. Nestelberger, D. Wussler, J. Walter, F.J. Martin-Sanchez, N. Geigy, et al. 2019. Early diagnosis of myocardial infarction in patients with a history of coronary artery bypass grafting. Journal of the American College of Cardiology 74 (4): 587\u2013589. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.044.","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"1158_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12013-015-0553-4","volume":"72","author":"L Lu","year":"2015","unstructured":"Lu, L., M. Liu, R. Sun, Y. Zheng, and P. Zhang. 2015. Myocardial infarction: Symptoms and treatments. Cell Biochemistry and Biophysics 72 (3): 865\u2013867. https:\/\/doi.org\/10.1007\/s12013-015-0553-4.","journal-title":"Cell Biochemistry and Biophysics"},{"key":"1158_CR5","doi-asserted-by":"publisher","unstructured":"Kim, C.Y., J.H. Lee, S.Y. Jang, M.H. Bae, D.H. Yang, H.S. Park, Y. Cho, et al. 2019. Usefulness of calculation of cardiovascular risk factors to predict outcomes in patients with acute myocardial infarction. The American Journal of Cardiology. https:\/\/doi.org\/10.1016\/j.amjcard.2019.06.010.","DOI":"10.1016\/j.amjcard.2019.06.010"},{"issue":"7","key":"1158_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-028939","volume":"9","author":"SRA Siri","year":"2019","unstructured":"Siri, S.R.A., B.M. Eliassen, B.K. Jacobsen, M. Melhus, A.R. Broderstad, V.L. Michalsen, and T. Braaten. 2019. Changes in conventional cardiovascular risk factors and the estimated 10-year risk of acute myocardial infarction or cerebral stroke in Sami and non-Sami populations in two population-based cross-sectional surveys: The SAMINOR study. BMJ Open 9 (7): e028939. https:\/\/doi.org\/10.1136\/bmjopen-2019-028939.","journal-title":"BMJ Open"},{"key":"1158_CR7","doi-asserted-by":"publisher","unstructured":"Sigirci, S., S.S. Yildiz, K. Keskin, G. Cetinkal, G. Aksan, A. Gurdal, S. Cetin, H. Kilci, and K.O. Kilickesmez. 2019. The predictive value of stress hyperglycemia on thrombus burden in nondiabetic patients with ST-segment elevation myocardial infarction. Blood Coagulation & Fibrinolysis. https:\/\/doi.org\/10.1097\/MBC.0000000000000832.","DOI":"10.1097\/MBC.0000000000000832"},{"key":"1158_CR8","doi-asserted-by":"publisher","unstructured":"Rauf, A., M. Shah, D.M. Yellon, and S.M. Davidson. 2019. The role of caspase 1 in ischemia\/reperfusion injury of the myocardium. Journal of Cardiovascular Pharmacology. https:\/\/doi.org\/10.1097\/FJC.0000000000000694.","DOI":"10.1097\/FJC.0000000000000694"},{"issue":"2","key":"1158_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jacc.2019.05.024","volume":"74","author":"B Ibanez","year":"2019","unstructured":"Ibanez, B., A.H. Aletras, A.E. Arai, H. Arheden, J. Bax, C. Berry, C. Bucciarelli-Ducci, et al. 2019. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. Journal of the American College of Cardiology 74 (2): 238\u2013256. https:\/\/doi.org\/10.1016\/j.jacc.2019.05.024.","journal-title":"Journal of the American College of Cardiology"},{"key":"1158_CR10","doi-asserted-by":"publisher","first-page":"172449","DOI":"10.1016\/j.ejphar.2019.172449","volume":"857","author":"J Hu","year":"2019","unstructured":"Hu, J., C.X. Huang, P.P. Rao, G.Q. Cao, Y. Zhang, J.P. Zhou, L.Y. Zhu, M.X. Liu, and G.G. Zhang. 2019. MicroRNA-155 inhibition attenuates endoplasmic reticulum stress-induced cardiomyocyte apoptosis following myocardial infarction via reducing macrophage inflammation. European Journal of Pharmacology 857: 172449. https:\/\/doi.org\/10.1016\/j.ejphar.2019.172449.","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"1158_CR11","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2174\/1570159X15666171123201142","volume":"16","author":"JC Felger","year":"2018","unstructured":"Felger, J.C. 2018. Imaging the role of inflammation in mood and anxiety-related disorders. Current Neuropharmacology 16 (5): 533\u2013558. https:\/\/doi.org\/10.2174\/1570159X15666171123201142.","journal-title":"Current Neuropharmacology"},{"key":"1158_CR12","doi-asserted-by":"publisher","unstructured":"Ablasser, A., and Z.J. Chen. 2019. cGAS in action: Expanding roles in immunity and inflammation. Science 363 (6431). https:\/\/doi.org\/10.1126\/science.aat8657.","DOI":"10.1126\/science.aat8657"},{"issue":"9","key":"1158_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.tibs.2018.06.008","volume":"43","author":"T Gong","year":"2018","unstructured":"Gong, T., W. Jiang, and R. Zhou. 2018. Control of inflammasome activation by phosphorylation. Trends in Biochemical Sciences 43 (9): 685\u2013699. https:\/\/doi.org\/10.1016\/j.tibs.2018.06.008.","journal-title":"Trends in Biochemical Sciences"},{"key":"1158_CR14","doi-asserted-by":"publisher","unstructured":"Shin, J.I., K.H. Lee, Y.H. Joo, J.M. Lee, J. Jeon, H.J. Jung, M. Shin, et al. 2019. Inflammasomes and autoimmune and rheumatic diseases: A comprehensive review. J Autoimmun: 102299. https:\/\/doi.org\/10.1016\/j.jaut.2019.06.010.","DOI":"10.1016\/j.jaut.2019.06.010"},{"key":"1158_CR15","doi-asserted-by":"publisher","unstructured":"Winsor, N., C. Krustev, J. Bruce, D.J. Philpott, and S.E. Girardin. 2019. Canonical and noncanonical inflammasomes in intestinal epithelial cells. Cell Microbiol: e13079. https:\/\/doi.org\/10.1111\/cmi.13079.","DOI":"10.1111\/cmi.13079"},{"key":"1158_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.pharmthera.2018.08.003","volume":"192","author":"J Henderson","year":"2018","unstructured":"Henderson, J., S. Bhattacharyya, J. Varga, and S. O\u2019Reilly. 2018. Targeting TLRs and the inflammasome in systemic sclerosis. Pharmacology & Therapeutics 192: 163\u2013169. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.08.003.","journal-title":"Pharmacology & Therapeutics"},{"key":"1158_CR17","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3389\/fimmu.2019.01592","volume":"10","author":"N An","year":"2019","unstructured":"An, N., Y. Gao, Z. Si, H. Zhang, L. Wang, C. Tian, M. Yuan, et al. 2019. Regulatory mechanisms of the NLRP3 inflammasome, a novel immune-inflammatory marker in cardiovascular diseases. Frontiers in Immunology 10: 1592. https:\/\/doi.org\/10.3389\/fimmu.2019.01592.","journal-title":"Frontiers in Immunology"},{"key":"1158_CR18","doi-asserted-by":"publisher","unstructured":"Kelley, N., D. Jeltema, Y. Duan, and Y. He. 2019. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. International Journal of Molecular Sciences 20 (13). https:\/\/doi.org\/10.3390\/ijms20133328.","DOI":"10.3390\/ijms20133328"},{"key":"1158_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fphar.2015.00262","volume":"6","author":"BZ Shao","year":"2015","unstructured":"Shao, B.Z., Z.Q. Xu, B.Z. Han, D.F. Su, and C. Liu. 2015. NLRP3 inflammasome and its inhibitors: A review. Frontiers in Pharmacology 6: 262. https:\/\/doi.org\/10.3389\/fphar.2015.00262.","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"1158_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrcardio.2017.161","volume":"15","author":"S Toldo","year":"2018","unstructured":"Toldo, S., and A. Abbate. 2018. The NLRP3 inflammasome in acute myocardial infarction. Nature Reviews. Cardiology 15 (4): 203\u2013214. https:\/\/doi.org\/10.1038\/nrcardio.2017.161.","journal-title":"Nature Reviews. Cardiology"},{"key":"1158_CR21","doi-asserted-by":"publisher","first-page":"105575","DOI":"10.1016\/j.intimp.2019.04.022","volume":"74","author":"R Gao","year":"2019","unstructured":"Gao, R., H. Shi, S. Chang, Y. Gao, X. Li, C. Lv, H. Yang, H. Xiang, J. Yang, L. Xu, and Y. Tang. 2019. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction. International Immunopharmacology 74: 105575. https:\/\/doi.org\/10.1016\/j.intimp.2019.04.022.","journal-title":"International Immunopharmacology"},{"key":"1158_CR22","doi-asserted-by":"publisher","unstructured":"Bian, Y., X. Li, P. Pang, X.L. Hu, S.T. Yu, Y.N. Liu, X. Li, N. Wang, J.H. Wang, W. Xiao, W.J. du, and B.F. Yang. 2019. Kanglexin, a novel anthraquinone compound, protects against myocardial ischemic injury in mice by suppressing NLRP3 and pyroptosis. Acta Pharmacologica Sinica: 1\u20138. https:\/\/doi.org\/10.1038\/s41401-019-0307-8.","DOI":"10.1038\/s41401-019-0307-8"},{"issue":"10","key":"1158_CR23","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1248\/bpb.33.1716","volume":"33","author":"T Yamazaki","year":"2010","unstructured":"Yamazaki, T., and T. Tokiwa. 2010. Isofraxidin, a coumarin component from Acanthopanax senticosus, inhibits matrix metalloproteinase-7 expression and cell invasion of human hepatoma cells. Biological & Pharmaceutical Bulletin 33 (10): 1716\u20131722. https:\/\/doi.org\/10.1248\/bpb.33.1716.","journal-title":"Biological & Pharmaceutical Bulletin"},{"issue":"8","key":"1158_CR24","doi-asserted-by":"publisher","first-page":"13302","DOI":"10.1002\/jcb.28604","volume":"120","author":"X Su","year":"2019","unstructured":"Su, X., B. Liu, F. Gong, J. Yin, Q. Sun, Y. Gao, Z. Lv, and X. Wang. 2019. Isofraxidin attenuates IL-1beta-induced inflammatory response in human nucleus pulposus cells. Journal of Cellular Biochemistry 120 (8): 13302\u201313309. https:\/\/doi.org\/10.1002\/jcb.28604.","journal-title":"Journal of Cellular Biochemistry"},{"issue":"8","key":"1158_CR25","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1039\/c7fo00290d","volume":"8","author":"J Li","year":"2017","unstructured":"Li, J., X. Li, Z. Li, L. Zhang, Y. Liu, H. Ding, and S. Yin. 2017. Isofraxidin, a coumarin component improves high-fat diet induced hepatic lipid homeostasis disorder and macrophage inflammation in mice. Food & Function 8 (8): 2886\u20132896. https:\/\/doi.org\/10.1039\/c7fo00290d.","journal-title":"Food & Function"},{"key":"1158_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.intimp.2018.09.003","volume":"64","author":"J Lin","year":"2018","unstructured":"Lin, J., X. Li, W. Qi, Y. Yan, K. Chen, X. Xue, X. Xu, Z. Feng, and X. Pan. 2018. Isofraxidin inhibits interleukin-1beta induced inflammatory response in human osteoarthritis chondrocytes. International Immunopharmacology 64: 238\u2013245. https:\/\/doi.org\/10.1016\/j.intimp.2018.09.003.","journal-title":"International Immunopharmacology"},{"issue":"3","key":"1158_CR27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.imbio.2014.10.007","volume":"220","author":"L Liu","year":"2015","unstructured":"Liu, L., Q. Mu, W. Li, W. Xing, H. Zhang, T. Fan, H. Yao, and L. He. 2015. Isofraxidin protects mice from LPS challenge by inhibiting pro-inflammatory cytokines and alleviating histopathological changes. Immunobiology 220 (3): 406\u2013413. https:\/\/doi.org\/10.1016\/j.imbio.2014.10.007.","journal-title":"Immunobiology"},{"key":"1158_CR28","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1038\/s41401-019-0230-z","volume":"40","author":"Q Liao","year":"2019","unstructured":"Liao, Q., S. Qu, L.X. Tang, L.P. Li, D.F. He, C.Y. Zeng, and W.E. Wang. 2019. Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis. Acta Pharmacologica Sinica 40: 1314\u20131321. https:\/\/doi.org\/10.1038\/s41401-019-0230-z.","journal-title":"Acta Pharmacologica Sinica"},{"issue":"3","key":"1158_CR29","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s10753-018-0945-x","volume":"42","author":"W Yu","year":"2019","unstructured":"Yu, W., G. Jin, J. Zhang, and W. Wei. 2019. Selective activation of cannabinoid receptor 2 attenuates myocardial infarction via suppressing NLRP3 inflammasome. Inflammation 42 (3): 904\u2013914. https:\/\/doi.org\/10.1007\/s10753-018-0945-x.","journal-title":"Inflammation"},{"issue":"2","key":"1158_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.intimp.2012.06.022","volume":"14","author":"X Niu","year":"2012","unstructured":"Niu, X., W. Xing, W. Li, T. Fan, H. Hu, and Y. Li. 2012. Isofraxidin exhibited anti-inflammatory effects in vivo and inhibited TNF-alpha production in LPS-induced mouse peritoneal macrophages in vitro via the MAPK pathway. International Immunopharmacology 14 (2): 164\u2013171. https:\/\/doi.org\/10.1016\/j.intimp.2012.06.022.","journal-title":"International Immunopharmacology"},{"issue":"2","key":"1158_CR31","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.intimp.2014.12.041","volume":"24","author":"X Niu","year":"2015","unstructured":"Niu, X., Y. Wang, W. Li, Q. Mu, H. Li, H. Yao, and H. Zhang. 2015. Protective effects of isofraxidin against lipopolysaccharide-induced acute lung injury in mice. International Immunopharmacology 24 (2): 432\u2013439. https:\/\/doi.org\/10.1016\/j.intimp.2014.12.041.","journal-title":"International Immunopharmacology"},{"issue":"4","key":"1158_CR32","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1248\/bpb.b18-00369","volume":"42","author":"M Takahashi","year":"2019","unstructured":"Takahashi, M. 2019. Role of NLRP3 inflammasome in cardiac inflammation and remodeling after myocardial infarction. Biological & Pharmaceutical Bulletin 42 (4): 518\u2013523. https:\/\/doi.org\/10.1248\/bpb.b18-00369.","journal-title":"Biological & Pharmaceutical Bulletin"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-019-01158-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10753-019-01158-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-019-01158-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T01:14:48Z","timestamp":1609982088000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10753-019-01158-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,8]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1158"],"URL":"https:\/\/doi.org\/10.1007\/s10753-019-01158-z","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,8]]},"assertion":[{"value":"8 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}